Pharvaris N.V. Ordinary Shares — Chart, Price & News (NASDAQ:PHVS) | MetaTrader

Open full chart

Financials

Overview Statement Statistics

Quarterly Annual

Market Capitalization 1.87 B
Employee 129
Founded 2015
CEO N/A
Website www.pharvaris.com
Headquarter Netherlands
FIGI UNKNOWN
Industry Technology

1.87 B Market capitalization

News

Pharvaris N.V. (PHVS) Presents at 2026 Global Angioedema Leadership Conference - Slideshow (NASDAQ:PHVS) 2026-03-28

Pharvaris publishes HAE patient study in medical journal

RBC Capital initiates Pharvaris stock at Outperform on HAE drug potential

Pharvaris reports positive phase 3 trial results for HAE drug

H.C. Wainwright reiterates Buy rating on Pharvaris stock with $60 target

Pharvaris anticipates phase 3 deucrictibant data for HAE prevention in 3Q2026

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema - Slideshow (NASDAQ:PHVS) 2025-12-09

Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals

Guggenheim raises Pharvaris stock price target to $39 on positive trial data

Pharvaris Surges, Pulling KalVista Out Of A Slump, On Promising New HAE Treatment

Pharvaris N.V. (PHVS) Discusses Topline Data From RAPIDe-3 Phase III Study of Deucrictibant for Hereditary Angioedema Transcript

Leerink Partners raises Pharvaris stock price target to $38 on positive trial data